DAF ACT Initiative to Support Domestic Manufacturing of Active Pharmaceutical Ingredients

DAF ACT Initiative

ISPE participated in the Department of the Air Force Acquisition COVID-19 Task Force (DAF ACT) to advise Regulatory, Technical, and Workforce elements favorable to creating a more robust and sustainable domestic pharmaceutical manufacturing base for Active Pharmaceutical Ingredients (APIs).

Under this partnership, ISPE assembled a task team of subject matter experts with in-depth knowledge in engineering, manufacturing, regulatory and compliance, environmental health & safety (EHS), analytical, and supply chain management. ISPE addressed challenges in these areas in the report “Increasing Domestic Resiliency in the Supply of Essential Active Pharmaceutical Ingredients.”

Published in December 2020, the report lays out technical, regulatory, and workforce changes that stakeholders in any country or region could consider to reduce the risks of API shortages to meet demands for essential medicines, in pandemics and other emergencies.

View the press release for additional information.

Regulatory Update

Download DAF ACT Report

To download this report, complete the form below. Once submitted, you will receive a link via the email you provided to download the report.

Company Type

By completing this form, you consent to have your information provided to the third-party sponsor of this content and may use your information to provide information about relevant products, services, and other opportunities which may be of interest to you . ISPE will store your information in a secure environment and may use your information to provide information about relevant products, services, and other opportunities which may be of interest to you. You may unsubscribe from these ISPE communications at any time. For more information or to unsubscribe, review our Privacy Policy or contact us at ask@ispe.org.